Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Adoptive transfer of HIV-specific CD8+ T cells, Aldesleukin; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: HIV-1-infection
Interventions: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 38
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: HIV Infections
Interventions: L-697,661, Zidovudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 1 more

Conditions: HIV
Interventions: TMC125, Darunavir; Ritonavir; Drug
Lead sponsor: Tibotec, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Delavirdine mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 87
States / cities: Birmingham, Alabama • Berkeley, California • Clovis, California + 63 more

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Birmingham, Alabama • Berkeley, California • Los Angeles, California + 22 more

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, pegylated interferon, ribavirin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Timeline: Started 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: HIV Infections
Interventions: Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 12 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Sherman Oaks, California + 15 more

Conditions: HIV Infections
Interventions: ACH126-443 (Beta-L-Fd4C); Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: Hepatitis C, Chronic
Interventions: GS-5885, Tegobuvir, GS-9451, ribavirin tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Anaheim, California + 34 more

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: HIV-1
Interventions: Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Syracuse, New York • Memphis, Tennessee

Conditions: Hepatitis C Infection
Interventions: MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2); Biological · Drug
Lead sponsor: MassBiologics; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, pegylated interferon; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Timeline: Started 2004
U.S. locations: 2
States / cities: Bradenton, Florida • San Antonio, Texas

Conditions: Cirrhosis, Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
Interventions: DUAL, QUAD; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease
Interventions: Doxorubicin, Methotrexate, Leucovorin, Hydroxyurea, Zidovudine, Rituximab; Drug · Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 2
States / cities: Miami, Florida • Chapel Hill, North Carolina

Conditions: Hepatitis C
Interventions: Eltrombopag, Antiviral therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more

Conditions: HIV-1-infection
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC); Drug
Lead sponsor: The Crofoot Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 5 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: HIV-1 Infection, Hepatitis C
Interventions: Ledipasvir/sofosbuvir, Ribavirin; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Hepatitis C, Chronic
Interventions: GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 54
States / cities: Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more

Search by objective public record fields.

Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults

Study of Novel Antiretrovirals in Participants With HIV-1

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection